Zealand Pharma A/S
Smedeland 26 B
Glostrup
DK-2600
Tel: 45-43-28-12-00
Fax: 45-43-28-12-12
Website: http://www.zp.dk/
Email: info@zp.dk
299 articles about Zealand Pharma A/S
-
Zealand Pharma Provides Update on Refocused Strategy Prioritizing Research and Development
5/12/2022
Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced financial results for the first three months of 2022.
-
Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities [CORRECTED]
5/12/2022
Zealand Pharma A/S announces that it has received information on transactions in Zealand shares or related securities by persons discharging managerial responsibilities.
-
Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022
5/10/2022
Zealand Pharma A/S announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:
-
Zealand Pharma Amends Financing Agreement with Oberland Capital as Part of Company’s Refocused Strategy
5/10/2022
Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced an amendment to its existing financing agreement with Oberland Capital Management LLC.
-
Zealand Pharma Hosts Conference Call on May 12 at 4 pm CET (10am ET) to Present First Quarter Results for 2022
5/5/2022
Zealand Pharma A/S announced that it will host a conference call on May 12, 2022 at 4 pm CET following the announcement of results for the first quarter of 2022.
-
Zealand Pharma major shareholder announcement: The Capital Group Companies, April 7 2022
4/7/2022
Zealand Pharma A/S announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:
-
Correction: Zealand Pharma major shareholder announcement: Polar Capital LLP, April 7 2022
4/7/2022
Zealand Pharma A/S announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:
-
Zealand Pharma to Participate in 21st Annual Needham Virtual Healthcare Conference
4/4/2022
Zealand Pharma A/S announced that Chief Executive Officer Adam Steensberg and Chief Financial Officer Matthew Dallas are scheduled to participate in the 21st Annual Needham Virtual Healthcare Conference.
-
Several employees at three biopharma firms are not having a very good week, as Zealand Pharma, Merck and Orchard Therapeutics all announced job cuts.
-
Zealand Pharma Appoints New Chief Executive Officer, Refocuses Strategy to Prioritize Research & Development and Streamlines Operations
3/30/2022
Zealand Pharma A/S a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced a corporate restructuring intended to leverage its peptide platform by prioritizing investment in its research and development pipeline programs and streamline its commercial operations.
-
Correction: Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022.
3/11/2022
Zealand Pharma A/S, a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, announced financial results for the 12-month period from January 1 to December 31, 2021.
-
Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022.
3/10/2022
Zealand Pharma:Significant Advancement of Clinical Pipeline and Building Commercial Momentum.
-
Zealand Pharma convenes its Annual General Meeting 2022
3/10/2022
Zealand Pharma A/S convenes the Annual General Meeting of the Company to be held on Wednesday April 6, 2022 at 3:00pm.
-
Zealand Pharma Hosts Conference Call on March 10 at 4 pm CET (10am ET) to Present Full Year Results for 2021
3/3/2022
Zealand Pharma A/S announced that it will host a conference call on March 10, 2022 at 4 pm CET following the announcement of results for the full year of 2021.
-
Zealand Pharma Completes Enrollment in Phase 3 Trial of Dasiglucagon in Children with Congenital Hyperinsulinism (CHI)
2/15/2022
Zealand Pharma A/S announced completion of patient enrollment in the second Phase 3-trial, 17103, of dasiglucagon for the treatment of Congenital hyperinsulinism in neonates up to 12 months old.
-
Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome
1/20/2022
Zealand Pharma A/S today announced completion of patient enrollment in its pivotal Phase 3 trial (EASE-SBS 1) of glepaglutide, the company’s long-acting GLP-2 analog, for the potential treatment of short bowel syndrome (SBS).
-
Zealand Pharma major shareholder announcement: The Capital Group Companies, January 2022
1/19/2022
Zealand Pharma A/S on pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders.
-
Zealand Pharma to Participate in H.C. Wainwright BIOCONNECT 2022 Conference
1/3/2022
Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate in the H.C. Wainwright BIOCONNECT 2022 Conference.
-
Total number of shares and voting rights in Zealand Pharma at December 30, 2021
12/30/2021
Zealand Pharma announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.